Angel Rodriguez-Chevres, MD
Psychiatry · El Paso, TXNPI 1285653089
Payments from drug & device makers
Across 221 payments — averaging $372.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$50K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$15K
- Teva Pharmaceuticals USA, Inc.$12K
- Sunovion Pharmaceuticals Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Johnson & Johnson$607
- plus $1K from 6 others
What the payments were for
- Consulting fees$5,7507%
- Speaking & faculty fees$62,66976%
- Travel & lodging$4,2105%
- Food & beverage$9,54212%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 53 | $50,332 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $15,355 |
| Teva Pharmaceuticals USA, Inc. | 24 | $12,345 |
| Sunovion Pharmaceuticals Inc. | 67 | $1,479 |
| Neurocrine Biosciences, Inc. | 14 | $1,087 |
| Johnson & Johnson | 7 | $607 |
| AbbVie(2 entities) | 11 | $399 |
| Corium, LLC | 4 | $262 |
| Avanir Pharmaceuticals, Inc. | 1 | $128 |
| Otsuka America Pharmaceutical, Inc. | 3 | $127 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$112,802
- LYBALVI$83,869
- ARISTADA INITIO$28,201
- CAPLYTA$14,877
- AUSTEDO$11,610
- LATUDA$483
- INGREZZA$453
- INVEGA SUSTENNA$353
- INVEGA TRINZA$228
- Azstarys$149
- NUEDEXTA$128
- VIVITROL$125
- VRAYLAR$125
- SPRAVATO$109
- UZEDY$107
How this compares
$82,282 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 31 | $11,578 |
| Lurasidone Hcl | 11 | $2,188 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 80 | $1,601 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $1,569 |
| Methylphenidate Hcl | 16 | $765 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $624 |
| Clonazepam | 58 | $479 |
| Haloperidol Decanoate | 13 | $366 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $311 |
| Ziprasidone Hcl | 11 | $277 |
| Buspirone Hcl | 27 | $237 |
| Hydroxyzine Hcl | 16 | $213 |
| Mirtazapine | 29 | $180 |
| Sertraline Hcl | 36 | $148 |
| Trazodone Hcl | 19 | $147 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in El Paso
- Martin GuerreroEl Paso$2M
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.